Search - tctmd.com

Displaying 301 - 320 of 785

Sort: Relevancy | Date

News Conference News EuroPCR 2018

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Shelley Wood

May 24, 2018

News Industry News

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

May 24, 2018

Presentation CIT 2018

A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease (FUTURE-I): Two-Year Clinical and Imaging Outcomes

Presenter: Bo Xu

March 23, 2018

News Industry News

Micell Technologies Announces Expanded Patent Estate - Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

March 21, 2018

News Conference News CRT 2018

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

Michael O'Riordan

March 08, 2018

News Industry News

REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold

February 26, 2018

Presentation JIM 2018

A New Generation Abluminal Coated Sirolimus Eluting Stent As A Treatment Option For Diabetic Patients

Presenter: Luca Testa

February 22, 2018

News Industry News

SELUTION™ First-in-Man Study Achieves Primary Endpoint

January 31, 2018

News Industry News

Positive Five-Year Data Published for MiStent in EuroIntervention

January 12, 2018

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

Presentation TCT 2017

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 2-Year Clinical Follow-Up

Presenter: Emmanouil S. Brilakis, Christopher E. Buller, Pieter R. Stella

November 01, 2017

Presentation TCT 2017

The Sirolimus-Eluting PLLA-Based Neovas Scaffold: Extended Results From the Randomized Trial

Presenter: Bernard R. Chevalier, Corrado Tamburino, Kai Xu

October 31, 2017

Presentation TCT 2017

Firehawk Sirolimus-Eluting Stent: Device Specifications and Clinical Program Update

Presenter: Manel Sabate, Joanna J. Wykrzykowska, Qi Zhang

October 31, 2017

Presentation TCT 2017

Abluminus Sirolimus-Eluting Stent: Specifications and Clinical Development

Presenter: Manel Sabate, Joanna J. Wykrzykowska, Luca Testa

October 31, 2017

Presentation TCT 2017

Outcomes With a Thin-Strut PLLA-Based Sirolimus-Eluting Stent 2: Inspiron

Presenter: Manel Sabate, Joanna J. Wykrzykowska, Pedro A. Lemos

October 31, 2017

Presentation TCT 2017

Outcomes With a Thin-Strut PLLA-Based Sirolimus-Eluting Stent 1: Biomime

Presenter: Manel Sabate, Joanna J. Wykrzykowska, Roberto Botelho

October 31, 2017

Presentation TCT 2017

TCT 13: A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I) - One-Year Clinical and Imaging Outcomes

Presenter: Stephan Achenbach, Jacques J. Koolen, Bo Xu

October 31, 2017

Presentation TCT 2017

The Orsiro Sirolimus-eluting Stent: Outcomes From the BIOFLOW and BIORESORT Trials

Presenter: Ioannis Iakovou, Gert Richardt, Clemens von Birgelen

October 30, 2017

Presentation TCT 2017

Small Vessel Stenting Snapshot 2: The Svelte Sirolimus-Eluting Stent

Presenter: Julinda Mehilli, Giulio G. Stefanini, Sunil V. Rao

October 30, 2017

Advertisement

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease (FUTURE-I): Two-Year Clinical and Imaging Outcomes

Micell Technologies Announces Expanded Patent Estate - Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold

A New Generation Abluminal Coated Sirolimus Eluting Stent As A Treatment Option For Diabetic Patients

SELUTION™ First-in-Man Study Achieves Primary Endpoint

Positive Five-Year Data Published for MiStent in EuroIntervention

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 2-Year Clinical Follow-Up

The Sirolimus-Eluting PLLA-Based Neovas Scaffold: Extended Results From the Randomized Trial

Firehawk Sirolimus-Eluting Stent: Device Specifications and Clinical Program Update

Abluminus Sirolimus-Eluting Stent: Specifications and Clinical Development

Outcomes With a Thin-Strut PLLA-Based Sirolimus-Eluting Stent 2: Inspiron

Outcomes With a Thin-Strut PLLA-Based Sirolimus-Eluting Stent 1: Biomime

TCT 13: A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I) - One-Year Clinical and Imaging Outcomes

The Orsiro Sirolimus-eluting Stent: Outcomes From the BIOFLOW and BIORESORT Trials

Small Vessel Stenting Snapshot 2: The Svelte Sirolimus-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content